BALVERSA
Total Payments
$306,145
Transactions
980
Doctors
698
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5,334 | 207 | 153 |
| 2023 | $87,689 | 58 | 50 |
| 2022 | $104,727 | 199 | 109 |
| 2021 | $31,306 | 87 | 65 |
| 2020 | $77,089 | 429 | 354 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $102,809 | 13 | 33.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $78,625 | 56 | 25.7% |
| Consulting Fee | $76,175 | 38 | 24.9% |
| Food and Beverage | $29,055 | 844 | 9.5% |
| Space rental or facility fees (teaching hospital only) | $11,400 | 5 | 3.7% |
| Travel and Lodging | $8,080 | 24 | 2.6% |
Payments by Type
General
$203,335
967 transactions
Research
$102,809
13 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 42756493BLC1002_Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations | Janssen Research & Development, LLC | $77,000 | 0 |
| Erdafitinib plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate Cancer | Janssen Research & Development, LLC | $25,809 | 0 |
Top Doctors Receiving Payments for BALVERSA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Orange, CA | $114,209 | 18 |
| , D.O | Medical Oncology | Atlantis, FL | $29,031 | 36 |
| , M.D | Hematology & Oncology | Nashville, TN | $17,414 | 15 |
| , M.D | Hematology & Oncology | Louisville, KY | $16,649 | 17 |
| , M.D., PH.D | Hematology & Oncology | Duarte, CA | $10,990 | 11 |
| , M.D | Urology | Houston, TX | $10,847 | 8 |
| , M.D | Internal Medicine | Littleton, CO | $9,221 | 7 |
| , M.D | Medical Oncology | Houston, TX | $7,813 | 14 |
| , M.D | Hematology & Oncology | New Haven, CT | $6,565 | 3 |
| , DR | Urology | Myrtle Beach, SC | $6,353 | 6 |
| , MD | Medical Oncology | New York, NY | $5,823 | 6 |
| , M D | Urology | Chicago, IL | $5,813 | 7 |
| , M.D | Hematology & Oncology | Houston, TX | $5,100 | 5 |
| , MD, PHD | Urology | Chicago, IL | $5,048 | 5 |
| Apurv Agrawal | — | Brick, NJ | $3,300 | 3 |
| , MD | Internal Medicine | New York, NY | $3,269 | 7 |
| , MD | Hematology & Oncology | Boston, MA | $3,188 | 4 |
| , M.D | Medical Oncology | Seattle, WA | $2,525 | 1 |
| , M.D | Urology | Los Angeles, CA | $2,145 | 1 |
| , M.D | Hematology & Oncology | New Orleans, LA | $1,603 | 3 |
| , MD, MBBS | Internal Medicine | Minneapolis, MN | $1,601 | 2 |
| , MD PHD | Internal Medicine | Boston, MA | $1,572 | 2 |
| , MD | Hematology & Oncology | Newport Beach, CA | $1,515 | 1 |
| , MD | Urology | Oklahoma City, OK | $1,515 | 1 |
| , MD | Internal Medicine | Salt Lake City, UT | $1,515 | 1 |
Ad
Manufacturing Companies
- Janssen Biotech, Inc. $142,442
- Janssen Research & Development, LLC $113,571
- Janssen Global Services, LLC $29,636
- Janssen Scientific Affairs, LLC $20,390
- Ethicon Inc. $104.42
Product Information
- Type Drug
- Total Payments $306,145
- Total Doctors 698
- Transactions 980
About BALVERSA
BALVERSA is a drug associated with $306,145 in payments to 698 healthcare providers, recorded across 980 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Biotech, Inc..
Payment data is available from 2020 to 2024. In 2024, $5,334 was paid across 207 transactions to 153 doctors.
The most common payment nature for BALVERSA is "Unspecified" ($102,809, 33.6% of total).
BALVERSA is associated with 2 research studies, including "42756493BLC1002_Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations" ($77,000).